Specific humoral response in cancer patients treated with a VEGF-specific active immunotherapy procedure within a compassionate use program.

ABSTRACT:

Background

CIGB-247 is a cancer therapeutic vaccine that uses as antigen a variant of human vascular endothelial growth factor (VEGF) mixed with the bacterially-derived adjuvant VSSP. CIGB-247 has been already evaluated in two phase I clinical trials (CENTAURO and CENTAURO-2), showing to be safe and immunogenic in advanced cancer patients selected under well-defined and controlled clinical conditions. Surviving patients were submitted to monthly re-immunizations and some of them showed objective clinical benefits. Based on these results, a compassionate use program (CUP) with CIGB-247 was initiated for patients that did not meet the strict entry criteria applied for the CENTAURO and CENTAURO-2 clinical trials, but could potentially benefit from the application of this cancer therap

SUBMITTER: Sanchez Ramirez J 

PROVIDER: S-EPMC7071683 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature